Arcturus’ has two proprietary technologies that solve the major hurdles in RNA medicine development. Our Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR™) delivery platform and our unlocked nucleomonomer agent (UNA) Oligomer™ technology can be used together or separately to create the next-generation of safe, effective RNA medicines.
LUNAR allows systemic delivery of all types of RNA therapeutics to target tissues. UNA oligomers are more stable, more potent and less toxic than standard oligomers.
We use our technologies in house, and partner with industry leaders, to discover and develop RNA medicines that treat rare and orphan diseases.
August 9, 2017
Arcturus Therapeutics in the list of Cystic Fibrosis Key Companies
July 13, 2017
Arcturus Therapeutics Inc. is Listed in the Key Players List; Involved in Non Alcoholic Steatohepatitis Pipeline (NASH)
July 7, 2017
The Korea Herald News on Arcturus Therapeutics Inc.